On August 26, in order to accelerate the cultivation of internationally competitive biomedical industry clusters and build an emerging biomedical pillar industry, the Jiangsu Provincial Department of Industry and Information Technology issued the “Jiangsu Three-Year Action Plan to Promote High-Quality Development of the Biomedical Industry”. The goal is to maintain the country's leading biomedical industry scale and number of innovative pharmaceutical devices by 2028, and build a number of biomedical industry clusters with core competitiveness. According to statistics from the Securities Times and Databao, according to the performance data currently disclosed, there are 112 biomedical stocks whose net profit increased by more than 20% year-on-year in the first half of 2026, according to the lower limit of semi-annual reports, performance reports, and forecasted net profit. The net profit of the eight stocks exceeded 1 billion yuan in the first half of the year, namely Pharmaceutical Ming Kangde, Rongchang Biotech, BaiGe Shenzhou, Jiu'an Healthcare, Jilin Aodong, Alice, Liaoning Chengda, and CSPC Innovation. Of the 112 high-growth biomedical stocks mentioned above, 29 had a rolling price-earnings ratio of less than 30 times as of the close of August 27. The rolling price-earnings ratio of Jiu'an Medical, Jilin Aodong, Rongchang Biotech, Tonghua Dongbao, Sansheng Guojian, and Deyuan Pharmaceutical is less than 15 times.

On August 26, in order to accelerate the cultivation of internationally competitive biomedical industry clusters and build an emerging biomedical pillar industry, the Jiangsu Provincial Department of Industry and Information Technology issued the “Jiangsu Three-Year Action Plan to Promote High-Quality Development of the Biomedical Industry”. The goal is to maintain the country's leading biomedical industry scale and number of innovative pharmaceutical devices by 2028, and build a number of biomedical industry clusters with core competitiveness. According to statistics from the Securities Times and Databao, according to the performance data currently disclosed, there are 112 biomedical stocks whose net profit increased by more than 20% year-on-year in the first half of 2026, according to the lower limit of semi-annual reports, performance reports, and forecasted net profit. The net profit of the eight stocks exceeded 1 billion yuan in the first half of the year, namely Pharmaceutical Ming Kangde, Rongchang Biotech, BaiGe Shenzhou, Jiu'an Healthcare, Jilin Aodong, Alice, Liaoning Chengda, and CSPC Innovation. Of the 112 high-growth biomedical stocks mentioned above, 29 had a rolling price-earnings ratio of less than 30 times as of the close of August 27. The rolling price-earnings ratio of Jiu'an Medical, Jilin Aodong, Rongchang Biotech, Tonghua Dongbao, Sansheng Guojian, and Deyuan Pharmaceutical is less than 15 times.